The Antidote for Blood Thinners
Bleeding can be a major concern for patients taking blood thinners. But what if the effects of these drugs could be safely reversed in an emergency situation?
How to Choose an Anticoagulant
If you need to take an anticoagulant — popularly known as a blood thinner — you don’t want it to cause bleeding, but some might raise your bleeding risk.
Blood Thinners Recommended for AFib Patients
People with atrial fibrillation, a common heart rhythm disorder, face a high likelihood of stroke. To reduce the risk, the American Academy of Neurology recommends taking anticoagulants.
FDA expands use of Xarelto to treat, reduce recurrence of blood clots
The US Food and Drug Administration today expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment.
FDA Rejects Rivaroxaban for ACS
Following a close vote, a U.S. Food and Drug Administration panel has declined to recommend r ivaroxaban ( Xarelto ) to treat acute coronary syndrome.
Risk High During Temporary Anticoagulant Halts
Patients with certain types of atrial fibrillation, a common heart arrhythmia, are at a high risk of stroke and blood clots if they temporarily stop their blood thinning medication before surgery or permanently because of side effects.
Rivaroxaban for Treating Pulmonary Embolism
New oral blood thinner rivaroxaban ( Xarelto ) has been shown to be safer for treating a pulmonary embolism as compared to enoxaparin ( Lovenox ) injections, and was found to be just as effective.
New Arrhythmia Drug Boasts Lower Brain Bleeding
Prior to its approval last year, there was much debate about Xarelto ( rivaroxaban ), an anti-clotting drug designed to prevent stroke among patients with atrial fibrillation, a common heart arrhythmia.
New Application for Bayer Heart Drug
Bayer’s cooperation partner, Janssen Research & Development, L.L.C. has submitted a Supplemental New Drug Application ( sNDA ) to the U.S. Food and Drug Administration (FDA) for the oral anticoagulant Xarelto ( rivaroxaban ) in combination with standard antiplatelet therapy to reduce the risk of (thrombotic) cardiovascular events in patients with Acute Coronary Syndrome (ACS).
FDA Approves Xarelto for Irregular Heartbeat
U.S. Food and Drug Administration officials have given the green light to anti-clotting drug Xarelto (rivaroxaban) to reduce the risk of stroke in patients with a common heart arrhythmia called atrial fibrillation.